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Abstract
Purpose Diagnosing Parkinson’s disease (PD) on clinical
grounds may be difficult, especially in the early stages of
the disease. F-DOPA PET and FP-CIT SPECT scans are
able to determine presynaptic dopaminergic activity in
different ways. The aim of this study was to determine and
compare the sensitivity and specificity of the two methods
in the detection of striatal dopaminergic deficits in the same
cohort of PD patients and healthy controls.
Methods Movement disorder specialists recruited 11
patients with early-stage PD and 17 patients with advanced
PD. The patients underwent both an FP-CIT SPECT scan
and an F-DOPA PET scan. In addition, 10 FP-CIT SPECT
scans or 10 F-DOPA PET scans were performed in 20
healthy controls. A template with regions of interest was
used to sample tracer activity of the caudate, putamen and a
reference region in the brain. The outcome parameter was
the striatooccipital ratio (SOR). Normal SOR values were
determined in the controls. The sensitivity and specificity of
both scanning methods were calculated.
Results FP-CIT SPECT and F-DOPA PET scans were both
able to discriminate PD patients from healthy controls. For
the early phases of the disease, sensitivity and specificity of
the contralateral striatal and putaminal uptake of FP-CIT
and F-DOPA was 100%. When only caudate uptake was
considered, the specificities were 100% and 90% for FP-
CIT and F-DOPA, respectively, while the sensitivity was
91% for both scanning techniques.
Conclusion FP-CIT SPECT and F-DOPA PET scans are
both able to diagnose presynaptic dopaminergic deficits in
early phases of PD with excellent sensitivity and specificity.
Keywords FP-CIT SPECT. F-DOPA PET.
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Introduction
Parkinson’s disease (PD) is a neurodegenerative disorder,
characterized by progressive loss of dopaminergic neurones
in the substantia nigra. In the early stages of the disease it
may be difficult to diagnose PD on the basis of clinical
signs and symptoms. Diagnosing PD can also be hampered
by the existence of nonneurodegenerative disorders, in
which the presynaptic dopaminergic system is still intact,
but which may mimic parkinsonism, such as essential tremor,
vascular parkinsonism or drug-induced parkinsonism. A
nonmovement disorder neurologist may misdiagnose up to
25% of patients with established parkinsonism of all sorts
when compared with post-mortem pathology [1, 2]. In
contrast, movement disorder specialists can almost always
correctly diagnose idiopathic PD when all the relevant
clinical information is obtained. In such circumstances, the
positive predictive value of the clinical diagnosis PD has
been found to be 98.6% [3]. These studies relate to patients
with advanced PD. No data are available to assess the
situation in patients with early undiagnosed PD who on
clinical grounds are indeed likely to have PD, but in whom
this cannot yet be confirmed by response to medication or by
the time course. This question is of even more interest for
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those patients in whom the clinician is not yet sure about the
diagnosis, but would like to know whether a striatal
dopaminergic defect is present or not [3]. Therefore, to
facilitate diagnosing PD in the above-mentioned circum-
stances, auxiliary examinations are needed. For this purpose,
conventional imaging techniques of the brain, such as CT
and MRI scans, are not useful, because the brain structure is
usually not greatly altered in early PD and dopaminergic
biochemical activity cannot be positively documented by
these techniques.
Radiotracer neuroimaging techniques using positron emis-
sion tomography (PET) or single photon emission computed
tomography (SPECT) can be helpful in visualizing and
measuring striatal dopaminergic activity [4, 5]. PET scans
using 6-[18F]fluoro-L-3,4-dihydroxyphenylalanine (F-DOPA)
enable measurement of striatal levodopa decarboxylase
activity and trapping of F-dopamine in synaptic vesicles,
which are decreased in PD [4–8]. It has been suggested that
in the early stages of this disease, levodopa decarboxylase
activity is upregulated [9, 10], although this has not yet been
proved. Such factors, however, may influence the sensitivity
of this technique for diagnosing defects in the nigrostriatal
system.
Using SPECT, the uptake of tracers with a high affinity
for the dopamine transporter (DAT) can be measured. DATs,
located on dopaminergic nerve endings, participate in the
reuptake mechanism of dopamine into presynaptic terminals
and are modulated by concentrations of endogenous
dopamine [11]. A decrease in DAT density in the striatum
has been associated with PD [12, 13]. DAT imaging can
therefore be used as a marker for the degree of malfunction
or loss of dopaminergic nerve endings. A selective and
potent DAT imaging agent is [123I]N-ω-fluoropropyl-2β-
carbomethoxy-3β-(4-iodophenyl) nortropane (FP-CIT).
SPECT imaging with FP-CIT produces a high target to
background ratio. Several studies have demonstrated that
striatal FP-CIT uptake is reduced in patients with PD
compared to healthy controls [14–22]. It has been shown
that striatal uptake values of FP-CIT SPECT and F-DOPA
PET correlate well with each other in patients with different
stages of PD [15, 23].
It has been suggested that DATs are downregulated as an
early response to reduction of the amount of endogenous
dopamine. This would result in a decreased striatal binding
of FP-CIT in early phases of PD. Therefore FP-CIT might
be more sensitive than F-DOPA for detecting early striatal
dopaminergic deficits.
The aim of this study was to determine and to compare
intraindividually the sensitivity and specificity of the two
tracer methods in the detection of striatal dopaminergic
nerve terminal malfunctioning in the same cohort of PD
patients and healthy controls.
Materials and methods
Patients
A total of 29 consecutive patients with strong clinical
evidence of having PD were recruited between 2002 and
2003 from the Movement Disorders outpatient clinic of
the University Hospital of Groningen, which has a tertiary
referral function. Enrolment and clinical evaluation of
participating patients was standardized and carried out by
experienced movement disorder specialists. At clinical
follow-up after more than 1 year after the two scans, 28
of the patients were still diagnosed with PD, confirmed by
a documented response on symptomatic antiparkinson
medication or, in drug-naive patients at follow up,
worsening of extrapyramidal signs without any other
symptoms. One patient did not respond to symptomatic
antiparkinson medication and did not show any worsening
of extrapyramidal signs after a period of 3 years of clini-
cal follow-up. This patient was therefore excluded from
further analyses.
The patients were divided into two groups: 11 patients (8
men and 3 women) with early-stage PD and 17 patients (15
men and 2 women) with advanced PD. The 11 patients with
early-stage PD showed strong clinical evidence of PD based
on two of the three cardinal symptoms (rest tremor,
bradykinesia and rigidity), had a disease duration of less
than 3 years, were not using antiparkinson medication, and
had a Hoehn & Yahr (H&Y) stage of less than 2.0. The 17
patients with advanced PD showed two of the three cardinal
symptoms, had a disease duration of 5–15 years, were using
antiparkinson medication with a documented response, and
had a H&Y stage of 2.0–4.0. Patients with atypical signs,
psychiatric disorders, signs of severe cognitive deterioration,
severe cardiovascular comorbidity or on medication known
to interfere with the DAT or catechol O-methyltransferase
inhibitors, were excluded from the study.
A total of 20 healthy controls, 11 men and 9 women, in
the same age range as the patients, were recruited. Subjects
with psychiatric disorders, signs of severe cognitive
deterioration, severe cardiovascular comorbidity or on
medication known to interfere with the DAT, were excluded
from the study.
Each patient with PD underwent a [123I]FP-CIT SPECT
scan and a one-time-frame static F-DOPA PET scan. Ten
healthy controls underwent a [123I]FP-CIT SPECT scan and
ten others underwent a static F-DOPA PET scan. Written
informed consent was obtained according to the Helsinki
Convention and the study was approved by the local
medical ethics committee. The ethics committee did not
allow performance of both F-DOPA and FP-CIT scans in
the same healthy control subjects.
Eur J Nucl Med Mol Imaging (2009) 36:454–462 455
F-DOPA PET scans
Subjects fasted for at least 4 h before the start of the scan.
Patients were allowed to continue their antiparkinson
medication. On arrival subjects were given carbidopa
(2.5 mg/kg) orally, and 60 min after the carbidopa dose,
received 200 MBq of F-DOPA intravenously. F-DOPA was
prepared in the radiochemical laboratory of the University
Medical Center Groningen as described elsewhere [24].
After a further 90 min from administration of the tracer, the
subject was positioned in the PET camera (Siemens HR+;
Erlangen, Germany) in a comfortable head holder with the
orbitomeatal line in a transverse plane and a one-time-frame
3-D acquisition of 6 min duration was performed according
to the standard operating procedures protocol of the
University Medical Center Groningen. In daily clinical
practice, static scans are preferred to dynamic scans in
patients with PD as dynamic scans take a long time to
perform and are therefore inconvenient. For estimation of
the diagnostic value in this patient group it was therefore
decided to perform static and not dynamic scans. Further-
more, static F-DOPA PET scans are preferred for a correct
comparison with (static) FP-CIT SPECT scans. Finally, it is
suggested that the striatal-occipital ratio (SOR) determined
from a static scan can be as accurate as kinetic parameters,
such as the binding constant K(occ), from a dynamic scan
[25]. Scan data were reconstructed using iterative methods
(ordered subsets expectation maximization) and were
corrected for attenuation using a separate ellipse algorithm,
according to the standard operating procedure in our centre
for clinical PET scans.
FP-CIT SPECT scans
Patients were allowed to continue all medication, including
antiparkinson medication. Subjects were injected with
185 MBq FP-CIT (DaTscan, obtained commercially from
GE, Eindhoven, The Netherlands). No thyroid blocking
was given. After 180 min a SPECT acquisition was
performed using a dual head gamma camera (Multispect
2; Siemens, Hoffman Estates, IL) with a LEHR (low-energy
high-resolution) collimator, 128×128 image matrix, zoom
factor 1.23, 40 s per view and 2×64 views. Data acquisition
was in agreement with the Dutch National Guidelines and
with the guidelines from the manufacturer. Acquisition time
was approximately 45 min. Images were acquired in a
symmetric 15% energy window around the photopeak of
123I at 159 keV. The system resolution was 12 mm FWHM
at 10 cm. Subjects were carefully positioned in the gamma
camera in a special head-holder which allowed minimal
rotational distance with the orbitomeatal axis in a transverse
plane to avoid reorientation during reconstruction. Image
data were reconstructed using filtered back-projection and a
Butterworth (0.50/6) filter. No attenuation correction was
performed. As the aim of our study was to compare the two
scanning methods in daily clinical practice, reconstruction
of data were performed according to the standard operating
procedures in our centre.
Image analysis
Reconstructed PET and SPECT data were realigned [26] to
the common coordinate system of the Stereotactic Brain
Atlas of Talairach and Tournoux. This realignment was
performed using standard linear brain normalization algo-
rithms (SPM software, FIL, London, UK). An image
analysis algorithm was used to remove skin uptake. A
standard set of regions of interest (ROIs) was used to
sample both the caudate and putamen and a nonspecific
reference region in the occipital cortex.
Ratios of specific to non-specific binding (SOR) were
calculated by dividing the striatal count density by the
occipital count density. ROI size-weighted average uptake
values of the caudate and putamen were used to calculate
mean whole striatal binding. In patients, uptake values in
the same half of the body as the dominant (and generally
initial) side of motor symptoms were called ipsilateral
uptake values and those opposite to that side were called
contralateral uptake values.
Statistical analysis
Shapiro-Wilk test was used to examine the normality of the
distributions of the parameters of the different datasets.
Normal values were calculated as the mean of all healthy
controls ±2 standard deviations (SD).
Mean values in subgroups were compared using Student’s
t test, and t tests were also used to determine if uptake
values in male controls differed significantly from those in
female controls. If values were not normally distributed,
Wilcoxon’s rank sum was used. One-sided p values of less
than 0.05 were considered statistical significant.
The results of the FP-CIT SPECTand F-DOPA PETscans
were initially considered abnormal when the uptake values
were less than the mean values minus 2 SD of the healthy
controls. Next receiver operating curves (ROC) were
produced and the sensitivity and specificity of the two
scanning techniques for discriminating patients with early-
stage PD from healthy controls were calculated. Sensitivity
and specificity of F-DOPA and FP-CIT scans were compared
using McNemar test. For determining the correlation
between uptake values and age, Pearson’s product was used
if the data were normally distributed and Spearman’s rho if
the data were not normally distributed.
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Results
Group characteristics
The mean age of the healthy controls was 60.8 years (SD 8.4,
range 40–74 years), the mean age of the patients with early-
stage PD was 51.3 years (SD 10.1, range 33–66 years), and
the mean age of the patients with advanced PD was
64.5 years (SD 6.3, range 46–71 years; see Table 1). The
ages of the two groups of healthy controls were similar
(t test, p=0.78). The age of the healthy controls was not
significantly different from the ages of the patients in both
groups (t test, p=0.42). However, as expected, the age of
patients with advanced disease was higher than the age of
patients with early-stage disease (t test, p=0.001). There
was no significant difference in age between patients with
advanced disease and healthy controls (t test, p=0.36).
The male:female ratio was similar in the two patient
groups (chi-squared test; p=0.30). However, the male:
female ratio was higher in patients than in controls (chi-
squared test; p=0.04; see Table 1).
Group results
In the control subjects, the mean SOR values for the caudate,
putamen and striatum, respectively, were 3.16 (range 2.70–
3.86, SD 0.38), 2.65 (range 2.39–3.06, SD 0.21) and 2.90
(range 2.74–3.28, SD 0.26) for FP-CIT, and 2.69 (range
2.32–3.17, SD 0.25), 2.70 (range 2.29–3.42, SD 0.30) and
2.69 (range 2.31–3.30, SD 0.27) for F-DOPA (see Table 2).
SORFP-CIT and SORF-DOPA for the left versus right caudate
and the left versus right putamen were identical in the
control subjects (all p>0.2). Examples of F-DOPA PET
scans and FP-CIT SPECT scans are shown in Fig. 1.
Disease discrimination
Contralateral values
The SORFPCIT and SORF-DOPA values for the caudate,
putamen and striatum contralateral to the symptomatic side
were significantly reduced in patients with early-stage PD
compared with controls (t test; p<0.0002 for all compar-
isons; see also Fig. 2). Ipsilateral uptake values were also
significantly reduced (t test; SORFP-CIT p<0.001 for all
comparisons). The measured uptake values of both tracers
for the contralateral putamen and striatum did not show any
overlap between patients and controls. However, these
groups could not be completely separated by means of the
calculated 2×SD interval (above and below the mean) of
SORF-DOPA for the contralateral putamen and striatum
(Table 2).
In patients with early-stage PD, sensitivity and specificity
based on contralateral putaminal and striatal SOR was 100%
for FP-CIT SPECT and for F-DOPA PET (see Table 3).
Sensitivity based on contralateral caudate uptake values
was the same (91%) for FP-CIT and F-DOPA, while
specificity was 90% for F-DOPA and 100% for FP-CIT.
The ROC showed area under the curve (AUC) values of
0.98, 1.00 and 1.00 for the contralateral caudate, putaminal
and striatal values, respectively, of FP-CIT, and AUC
values of 0.95, 1.00 and 1.00 for the contralateral caudate,
putaminal and striatal values, respectively, of F-DOPA. For
the whole group of patients with early and advanced
stages of disease, the specificity and sensitivity were 1.00
for both contralateral putaminal and striatal SORFP-CIT and
SORF-DOPA (see Table 3). Also the AUC values of the ROC
curves were equal for FP-CIT and for F-DOPA uptake for
the contralateral putamen and striatum. There were no
significant differences in sensitivity and specificity between
the two scanning techniques (McNemar test).
Ipsilateral values
When the analysis of disease discrimination was restricted
to patients with H&Y stage 1 (i.e. one-sided parkinsonism
without axial problems; n=4) and controls, ipsilateral
uptake values were also significantly reduced in patients,
albeit to a lesser degree (t test: SORFP-CIT p=0.0007 for the
caudate, p=0.0002 for the putamen and p<0.0001 for the
striatum; SORF-DOPA p=0.0141 for the caudate, p=0.0097
for the putamen and p=0.0091 for the striatum).
Table 1 Subject characteristics
Controls Early-stage patients Advanced-stage patients
FP-CIT F-DOPA FP-CIT F-DOPA FP-CIT F-DOPA
No. of subjects 10 10 11 11 17 17
Men 5 5 8 8 15 15
Women 5 5 3 3 2 2
Age (years)
Mean 60.2 61.4 51.3 51.3 64.5 64.5
SD 8.7 8.5 10.1 10.1 6.3 6.3
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Normal ageing
In the group of 20 controls (n=10 for each tracer), we
found a significant age-dependent decline in SORFP-CIT of
4.6% per decade for the mean putamen and of 3.9% per
decade for the mean striatum (p=0.04 and 0.05, respec-
tively), but not for the mean caudate (p=0.33). No
significant effect of ageing was found for uptake values of
F-DOPA (p=0.75 for the mean caudate, p=0.65 for the
mean putamen and p=0.92 for the mean striatum).
Gender differences
In the group with healthy controls we found no significant
effect of gender on striatal uptake of FP-CIT (t test: p=0.77
for the caudate, p=0.08 for the putamen and p=0.50 for the
Table 2 Uptake values of healthy controls and PD patients
Subject group Region FP-CIT F-DOPA
Mean SD 2×SD interval Mean SD 2×SD interval
Controls (n=2×10) Mean caudate 3.16 0.38 2.54–3.78 2.69 0.25 2.19–3.19
Mean putamen 2.65 0.21 2.19–3.11 2.70 0.30 2.10–3.30
Mean striatum 2.90 0.26 2.50–3.10 2.69 0.27 2.15–3.23
Early-stage (n=11) Contralateral caudate 2.22 0.28 1.66–2.78 2.27 0.15 1.97–2.57
Contralateral putamen 1.82 0.16 1.50–2.14 1.91 0.15 1.61–2.21
Contralateral striatum 2.02 0.17 1.68–2.36 2.09 0.14 1.81–2.37
Advanced (n=17) Contralateral caudate 1.91 0.47 0.97–2.85 2.05 0.21 1.63–2.47
Contralateral putamen 1.60 0.21 1.18–2.02 1.76 0.11 1.54–1.98





Fig. 1 F-DOPA PET scans in
(a) healthy controls and (b)
patients with early-stage PD,
and FP-CIT SPECT scans in (c)
healthy controls and (d) patients
with early-stage PD
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striatum). For F-DOPA, females tended to have slightly
lower striatal uptake values than males. However, this
difference did not reach statistical significance (t test: p=
0.45 for the caudate, p=0.12 for the putamen and p=0.23
for the striatum).
Discussion
This study demonstrates that both FP-CIT SPECT and F-
DOPA PET scans are equally able to distinguish patients
with PD patients from healthy controls. Our data show that
scans with either tracer are able with 100% specificity and
sensitivity to detect nigrostriatal damage in a group of
patients with typical early-phase PD when considering
tracer uptake in the contralateral putamen or striatum.
To our knowledge only one previous study has com-
pared FP-CIT SPECT scans with F-DOPA PET scans in
patients with mild PD and healthy volunteers [15]. With
each method separately, they were able to identify correctly
all 15 healthy controls and 11 out of 12 PD patients. Others
reported a sensitivity of 95% to 97% for FP-CIT SPECT
[27, 28]. Morrish et al. were able to separate patients with
PD from the normal group completely by F-DOPA PET
[29]. Our findings emphasize the specificity of the applied
methods. In our earlier study we demonstrated that both FP-
CIT SPECT and F-DOPA PET can be used to measure the
presynaptic dopaminergic system in vivo and that they both
show equally good ability to separate the early from the
advanced stage of PD. Uptake values of F-DOPA correlated
well with FP-CIT uptake values [23].
Both tracers are in vivo markers of the presynaptic
dopaminergic system, but reflect different underlying
biochemical mechanisms. F-DOPA uptake reflects the
activity of aromatic L-amino acid decarboxylase (AADC)
in the nerve terminals of the nigrostriatal dopaminergic
pathway and the storage of F-dopamine in these nerve
terminals [4, 5]. FP-CIT binds to DATs, involved in the
reuptake of dopamine from the synaptic cleft [11]. This
difference between the two tracers results in a different
method for examining the presynaptic dopaminergic sys-
tem. In daily practice FP-CIT SPECT scanning is readily
Table 3 Sensitivity and specificity based on uptake values
Region FP-CIT F-DOPA
Sensitivity (%) Specificity (%) AUC Sensitivity (%) Specificity (%) AUC
Early-stage versus controls Contralateral caudate 91 100 0.98 91 90 0.95
Ipsilateral caudate 82 90 0.86 64 90 0.80
Contralateral putamen 100 100 1.00 100 100 1.00
Ipsilateral putamen 100 100 1.00 91 90 0.95
Contralateral striatum 100 100 1.00 100 100 1.00
Ipsilateral striatum 73 100 0.95 82 90 0.92
All patients versus controls Contralateral caudate 100 91 0.98 90 96 0.98
Ipsilateral caudate 100 82 0.94 90 86 0.91
Contralateral putamen 100 100 1.00 100 100 1.00
Ipsilateral putamen 100 96 0.99 100 89 0.98
Contralateral striatum 100 100 1.00 100 100 1.00
Ipsilateral striatum 100 86 0.98 90 93 0.97
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Fig. 2 Contralateral uptake values in healthy controls and patients
with early-stage PD for (a) FP-CIT and (b) F-DOPA (closed diamonds
healthy controls, open triangles patients with early-stage PD)
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applicable, in contrast to F-DOPA PET, whose use is
limited by restricted availability of PET instruments
and related tracer production. FP-CIT SPECT scanning,
assuming that a normal dataset is available as reference for
this technique, may therefore be the only realistic option to
obtain relevant in vivo data about striatal dopaminergic
activity. We found that in patients with likely early PD, a
dopaminergic defect can be detected with FP-CIT SPECT
scans as well as with F-DOPA PET scans. The finding of
defects in the presynaptic dopaminergic system can be
helpful for the physician to diagnose parkinsonian syn-
dromes correctly in patients with doubtful clinical extra-
pyramidal symptoms.
Lee et al. [10] have examined the uptake of different
tracers in patients with PD. They compared striatal uptake of
[11C]methylphenidate (labelling DAT, comparable to the way
FP-CIT does) with F-DOPA in patients with PD in an early
phase of the disease. They found that in mildly affected
parkinsonian patients, striatal F-DOPA uptake is relatively
higher than the uptake of methylphenidate in the caudate as
well as in the putamen. It was suggested that this difference
in tracer uptake could be the result of an upregulation of
AADC and a downregulation of the plasma membrane DAT
in the striatum of patients with early PD. No direct proof of
this has been obtained from human studies, although it is in
line with experimental animal studies, which suggest a com-
pensation of the loss of dopaminergic neurones by increasing
the relative synthesis and release of dopamine from the
remaining dopaminergic neurones [30, 31]. Ito et al. [9]
concluded that in rats with early to advanced parkinsonism
induced by 6-hydroxydopamine, [14C]L-DOPA levels
underestimated the decrease in dopaminergic neurones
and that [125I]β-CIT levels more precisely reflected the
decrease, suggesting that DAT is a better indicator of
dopaminergic neuron loss. According to our data, striatal
uptake of both tracers was reduced in patients with early-
stage PD compared to healthy controls and no significant
difference was found in disease discrimination between
the two tracers.
We found that using either tracer, the striatal uptake in
patients with unilateral PD (H&Y I) was significantly
reduced bilaterally without overlap of putamen values
between PD patients and healthy controls. This implies
that both methods can possibly also be used to identify
patients in a preclinical phase of the disease. This has been
confirmed by others [16, 18, 21].
Values of healthy controls are needed to interpret
correctly the results of functional neuroimaging. As
different institutions may use different ROIs or different
methods of analysis, each should obtain its own set of
normal data. Our striatal uptake values of FP-CIT were
higher than those of Innis et al. [32] and Tissingh et al.,
who found a striatal SOR in healthy controls of 2.24 and
2.43 [21]. Our caudate uptake values for FP-CIT were
much higher than putaminal uptake values for FP-CIT
(putamen:caudate ratio 0.83 for FP-CIT and 1.00 for F-
DOPA) in healthy controls. These high caudate uptake
values were consistent through the complete set of data and
could not be explained by outliers. Tissingh et al. found
similar high caudate:putamen ratios [21]. Other studies
have shown lower caudate uptake values in healthy
controls. Also our SORF-DOPA values were slightly higher
than those of Ishikawa et al. who found uptake values of
approximately 2.2 [15, 33].
One of the problems in evaluating neuroimaging methods
in patients with early-stage PD is the validity of the clinical
diagnosis of PD in this group. As mentioned before,
diagnosing PD correctly based on clinical symptoms can be
difficult and misdiagnosis occurs in up to 25% of patients in
general practice. We have tried to overcome this problem by
making the selection of participating patients by movement
disorder specialists and by evaluating the clinical diagnosis
after a period of more than 1 year after the performance of the
scans.
We found a significant age-dependent decline in SORFP-CIT
of 3.9% per decade in healthy controls, which is in line with
the findings of others [15, 34], and in a post-mortem study a
decay of 4.7% per decade of pigmented neurones in the
substantia nigra was demonstrated [35]. It has been
speculated that this ageing effect on DAT binding can be
explained by compensation of neuronal dopamine loss by
decreasing DAT synthesis [36]. Our study shows that the
ageing effect on striatal DAT binding is relatively small and
adjusting uptake values for age did not influence its accuracy
for diagnosing presynaptic dopaminergic deficit. Also no
significant effect of age on the symptomatic threshold of
disease in PD was reported by others [15, 37].
In our data, striatal F-DOPA uptake did not change with
age, although the number of subjects may have been too
small to detect any ageing effect. This is in agreement with
others [15, 38, 39], although some studies have shown an
ageing effect with F-DOPA PET [40, 41]. This doubtful
effect of ageing on F-DOPA uptake may perhaps be
explained by a lack of AADC decline during ageing [42],
which is supported by post-mortem studies, indicating no
decrease in AADC activity with age [43]. Another
explanation may be that the remaining neurons produce
less tyrosine hydroxylase (TH) per neuron resulting in a
decrease in endogenous dopamine, while AADC and
storage capacity for dopamine is maintained [44].
We found no significant effect of gender on striatal
uptake values of either FP-CIT or F-DOPA in healthy
controls. This is in agreement with some studies which also
could not detect an effect of gender on FP-CIT uptake or F-
DOPA uptake [45, 46]. However, other studies have
suggested that DAT tracer and F-DOPA uptake values are
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higher in women than in men [34, 47–49]. The lack of a
significant effect of gender on striatal uptake values in our
study may also be explained by the small number of
participating healthy controls.
In this study we examined the uptake of two tracers in
the same patients with clinically strong evidence of having
PD, also after a longer period of time. According to our
study FP-CIT SPECT scans as well as F-DOPA PET scans
are both able to detect early striatal dopaminergic defects
and may therefore be of great help for the physician to
diagnose PD correctly in an early phase of the disease.
Patients with normal striatal uptake need to be reconsidered
in terms of clinical condition. A person with clinical signs
and symptoms which suggest parkinsonism but with normal
striatal FP-CIT or F-DOPA uptake is not suffering from PD.
However, it must be borne in mind that finding a striatal
uptake reduction of either tracer does not provide by itself a
clinical diagnosis of PD or other brain disease, but only
demonstrates a striatal dopaminergic biochemical lesion.
Conclusion
Our study demonstrates that both FP-CIT SPECT scans and
F-DOPA PET scans are able to diagnose presynaptic
dopaminergic dysfunction and to separate patients with
PD from healthy controls with high values of sensitivity
and specificity.
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